Versartis, a biotech developing long-acting treatments for growth hormone deficiency, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $81 million by offering 4.6 million shares at a price range of $16 to $19. At the midpoint of the proposed range, it would command a fully diluted market value of $409 million. Versartis was founded in 2008 and plans to list on the NASDAQ under the symbol VSAR. Versartis initially filed confidentially on January 10, 2014. Morgan Stanley and Citi are the joint bookrunners on the deal.
